Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70223

Title: Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02623966
Position: Editorial Board
Academic degree: MD, MSc, PhD
Professional title: Attending Doctor, Research Scientist
Reviewer's Country/Territory: Greece
Author's Country/Territory: China

Manuscript submission date: 2021-07-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-30 17:46

Reviewer performed review: 2021-07-30 17:46

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [Y] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [ ] Anonymous [Y] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

It is a well-design study adding new information to the literature. Authors in a clear and simply way managed to give their results as well as the relative literature. I have no comments to make and in my opinion the article can be published unaltered.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70223

Title: Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05430684
Position: Peer Reviewer
Academic degree: MD, MSc, PhD
Professional title: Chief Doctor
Reviewer's Country/Territory: Greece
Author's Country/Territory: China

Manuscript submission date: 2021-07-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-28 14:09

Reviewer performed review: 2021-07-31 15:59

Review time: 3 Days and 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I studied the manuscript entitled "A novel HNF1A gene mutation in maturity-onset diabetes of the young" by Xu et al. It deals with a well-documented case of MODY3 attributed to a novel mutation. The information provided is of great interest to all specialists focusing on diabetes and, as such, deserves prioritized publication.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70223

Title: Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03673990
Position: Peer Reviewer
Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Poland

Author's Country/Territory: China

Manuscript submission date: 2021-07-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-31 07:50

Reviewer performed review: 2021-08-05 13:11

Review time: 5 Days and 5 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The presented manuscript titled "A novel HNF1A gene mutation in maturity-onset diabetes of the young" brings new data to the pool of genetical aspects od MODY type diabetes. The paper is based on the analysis of medical history of young man of Asiatic origin developing non-insulin-dependent diabetes present in two generations of his family. Major comments: The medical history of the patient is not fully described, some information is missing. There are no data about the presence of glycosuria, as well about the length of the time the patient has been treated with metformin, saxagliptin and glargine. Some data is redundant unnecessarily, e.g. twice the HBA1c level at the beginning of the therapy, while the final effect after the inclusion of the SU in the therapy. The dose of glibenclamide appears only in the discussion. The authors do not mention about the imaging test results. The study lacks a description of the research methods. Only in Figure 1 there is a signature that this is Sanger sequencing. Minor comments: line 50 – has to be "replaced" instead of "rheplaced" Finally the paper is worth publishing after revision.

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 70223

Title: Novel HNF1A gene mutation in maturity-onset diabetes of the young: A case report

Provenance and peer review: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06011815
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2021-07-28

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-02 10:57

Reviewer performed review: 2021-08-06 11:25

Review time: 4 Days

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [ ] Grade C: Good [Y] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [Y] Major revision [ ] Rejection
Re-review	[Y] Yes [ ] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

In this manuscript, the authors presented an interesting case about HNF1A gene mutation in a 22-year-old MODY3 patient. The mutation resluted in a good repsonse to sulfonylurea therapy. Generally I think the topic is very interesting and the approach is attractive, but I simply could not follow how the authors framed and then conducted their analysis. In order to make the draft more illustrated, the authors should add some contents in the disscusion for how sulfonylurea benifit from the mutation in glycemic control.